国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (5): 386-389.doi: 10.3760/cma.j.issn.1673-422X.2014.05.020

• 论著 • 上一篇    下一篇

5-氮杂-2′脱氧胞苷对人卵巢癌细胞株RASSF1A基因表达的影响

徐华平,位玲霞,董延磊,张师前   

  1. 250001济南，山东大学齐鲁医院妇科（徐华平、董延磊、张师前）；山东中医药大学第二附属医院妇产科（徐华平）；济宁医学院临床学院（位玲霞）
  • 收稿日期:2013-10-14 修回日期:2014-01-10 出版日期:2014-05-08 发布日期:2014-04-28
  • 通讯作者: 张师前 E-mail:zhangshiqian370112@126.com

Effects of 5-aza-2′deoxycitydine on expression of RASSF1A gene in human ovarian cancer cell line

Xu Huaping, Wei Lingxia, Dong Yanlei, Zhang Shiqian   

  1. Department of Gynecology, Qilu Hospital of Shandong University; Department of Obstetrics and Gynecology, Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji′nan 250001, China
  • Received:2013-10-14 Revised:2014-01-10 Online:2014-05-08 Published:2014-04-28
  • Contact: Zhang Shiqian E-mail:zhangshiqian370112@126.com

PDF

1209

摘要： 目的 观察5-氮杂-2′脱氧胞苷（5-Aza-CdR）对体外培养的人卵巢癌细胞株（SKOV3、3AO）RASSF1A mRNA及蛋白表达的影响。方法 卵巢癌细胞株（SKOV3、3AO）经不同浓度（0.5、5、50 μmol/L）的5-Aza-CdR处理，未经处理的作为对照组，反转录聚合酶链反应(RTPCR)及免疫印记（Western Blot）检测RASSF1A在mRNA和蛋白质水平表达的变化。结果 对照组细胞株SKOV3、3AO均可见RASSF1A mRNA及蛋白的表达，但表达较弱，经药物处理后的细胞RASSF1A mRNA及蛋白的表达较前明显增强。经不同浓度5-Aza-cdR处理的SKOV3细胞株中，随浓度增加，RASSF1A mRNA及蛋白的表达依次递增。经不同浓度5-Aza-cdR处理的3AO细胞株中，经0.5 μmol/L 5AzacdR处理后，RASSF1A mRNA的表达明显低于经5和50 μmol/L 5AzacdR处理后的表达（t=-8.866，P=0.01；t=-12.256，P=0.000）；但经5、50 μmol/L 5-Aza-cdR分别处理的3AO细胞株RASSF1A mRNA的表达差异无统计学意义（t=0.431，P=0.689）。在3AO细胞株中，0.5 μmol/L组与5 μmol/L组RASSF1A蛋白表达差异无统计学意义（t=-1.586，P=0.188）。结论 经过5AzaCdR处理后，卵巢癌细胞株（SKOV3、3AO）RASSF1A mRNA及蛋白的表达均明显增强，细胞增殖能力受到明显抑制，从而起到抑制肿瘤细胞生长，甚至促进肿瘤细胞凋亡的作用。

关键词: 卵巢肿瘤, RASSF1A基因, 5-氮杂-2&prime, 脱氧胞苷

Abstract: Objective To investigate the effect of 5-aza-2′deoxycytidine (5-Aza-CdR) on proliferation and expression of RASSF1A gene in human ovarian cancer cell line SKOV3 and 3AO. MethodsSKOV3 and 3AO cells were treated with different concentrations (0.5, 5, 50 μmol/L) of DNA methyltransferase inhibitor 5-Aza-CdR. RT-PCR and Western Blot were adopted to detect expression of mRNA and protein of RASSF1A gene before and after treatment with 5-Aza-CdR respectively. ResultsCompared with control group, when the 5-Aza-CdR concentration was 0.5, 5, 50 μmol/L after drug treatment, human ovarian cancer cells could significantly inhibit tumor cell growth; SKOV3 and 3AO cells in control group were observed weaker expression of RASSF1A mRNA. After treated with 5-Aza-CdR, the expressions of RASSF1A mRNA were observed  increased  with the increase of the drug concentration. After treated with different concentration of 5-Aza-CdR, the expressions of RASSF1A mRNA treated with 0.5 μmol/L 5-Aza-cdR was lower than those treated with 5 and 50 μmol/L 5-Aza-cdR (t=-8.866, P=0.01; t=-12.256, P=0.000). However, expressions of RASSF1A mRNA treated with 5 and 50 μmol/L 5-Aza-cdR respectively showed no statistical significance (t=0.431, P =0.689). Expressions of RASSF1A protein treated with 0.5 μmol/L 5-Aza-cdR and 5 μmol/L 5-Aza-cdR didn′t show statistically significant (t=-1.586, P=0.188). ConclusionExpressions of RASSF1A mRNA and protein in SKOV3 and 3AO cells were evidently enhanced. As one kind of methyltransferases inhibitors, 5-Aza-CdR can inhibit ovarian cancer cell line SKOV3, 3AO growth through the RASSF1A promoter methylation, and thus promote their apoptosis.

Key words: Ovarian neoplasms, RASSF1A gene, 5-aza-2′deoxycytidine